Marrache Majd, Bronheim Rachel, Harris Andrew B, Puvanesarajah Varun, Raad Micheal, Lee Sang, Skolasky Richard, Jain Amit
Department of Orthopaedic Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Neurospine. 2020 Dec;17(4):896-901. doi: 10.14245/ns.2040216.108. Epub 2020 Dec 31.
The aim of this study was to compare all-cause reoperation rates and costs in nonelderly patients treated with anterior cervical discectomy and fusion (ACDF) with structural allograft versus synthetic cages for degenerative pathology.
We queried a private claims database to identify adult patients ( ≤ 65 years) who underwent single-level ACDF in a hospital setting using either structural allograft or a synthetic cage (polyetheretherketone, metal, or hybrid device), from 2010 to 2016. The rate of all-cause reoperations at 2 years were compared between the 2 groups. Index hospitalization costs and 90-day complication rates were also compared. Significance was set at p < 0.05.
A total of 26,754 patients were included in the study. 11,514 patients (43%) underwent ACDF with structural allograft and 15,240 (57%) underwent ACDF with a synthetic cage. The patients in the allograft group were younger and more likely to be male. There was no significant difference between the 2 groups with respect to 90-day complications including: wound dehiscence, dysphagia, dysphonia, and hematoma/seroma. In the 2-year postoperative period, the synthetic cage group had a significantly higher rate of allcause reoperation compared to the allograft group (9.1% vs. 8.0%, p = 0.002). Index hospitalization costs were significantly higher in the synthetic cage group compared to those in the allograft group ($23,475 vs. $20,836, p < 0.001).
Structural allograft is associated with lower all-cause reoperation rates and lower index costs in nonelderly patients undergoing ACDF surgery for degenerative pathology. It is important to understand this data as we transition toward value-based care.
本研究旨在比较接受前路颈椎间盘切除融合术(ACDF)治疗退行性病变的非老年患者使用结构性同种异体骨与人工椎间融合器的全因再次手术率及费用。
我们查询了一个私人理赔数据库,以确定2010年至2016年期间在医院接受单节段ACDF手术,使用结构性同种异体骨或人工椎间融合器(聚醚醚酮、金属或混合装置)的成年患者(≤65岁)。比较两组患者2年时的全因再次手术率。还比较了首次住院费用和90天并发症发生率。显著性设定为p<0.05。
共有26754例患者纳入本研究。11514例患者(43%)接受了使用结构性同种异体骨的ACDF手术,15240例患者(57%)接受了使用人工椎间融合器的ACDF手术。同种异体骨组患者更年轻,男性比例更高。两组在90天并发症(包括伤口裂开、吞咽困难、声音嘶哑和血肿/血清肿)方面无显著差异。术后2年,人工椎间融合器组的全因再次手术率显著高于同种异体骨组(9.1%对8.0%,p=0.002)。人工椎间融合器组的首次住院费用显著高于同种异体骨组(23475美元对20836美元,p<0.001)。
对于因退行性病变接受ACDF手术的非老年患者,结构性同种异体骨与较低的全因再次手术率和较低的首次费用相关。在我们向基于价值的医疗转变过程中,了解这些数据很重要。